Sinaptica Therapeutics
Lisa Fosdick has over three decades of work experience in the healthcare and medical device industry. Lisa has held various leadership roles in organizations such as Sinaptica Therapeutics, Functional Neuromodulation, Crucial Life Sciences Data Solutions, NAMSA, The Integra Group, CVRx, and CCBR/UM. Their experience includes overseeing global clinical operations, managing clinical teams, building data management services, and providing expertise in data analysis and interpretation. Lisa has also played a key role in the successful enrollment of clinical trials and has collaborated with regulatory authorities.
Lisa Fosdick has a Bachelor of Science (BS) degree in Biochemistry, as well as a BS in Genetics and Cell Biology, from the University of Minnesota. Lisa also holds a Master of Science (MS) degree in Biostatistics from the University of Minnesota School of Public Health.
This person is not in any teams
This person is not in any offices
Sinaptica Therapeutics
Sinaptica Therapeutics™ is a Cambridge MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease (AD). The company was founded by two top clinical researchers in the field of noninvasive brain modulation for neurodegenerative disorders, together with support from biotech, digital health, and medical device industry executives. The company’s SinaptiStim™ System represents a totally new approach to treating AD by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory, and has been granted FDA Breakthrough Designation based on unprecedented published Phase 2 sham-controlled data that achieved statistical significance on all four gold-standard cognitive & functional clinical endpoints. Sinaptica is building upon over a decade of research on innovative brain targeting methods, biophysical modeling, and noninvasive treatment protocols leveraging machine learning on proprietary datasets to create a foundational leap in personalized precision electromagnetic therapeutics. Based on highly significant published sham-controlled data, the company's neurostimulation device and integrated personalization engine has the potential to become one of the most clinically-effective treatments to reach Alzheimer’s patients in over two decades, and is protected by multiple pending patents.